Belite Bio, INC Form 4 insider transactions

Hao-Yuan Chuang, Chief Financial Officer and a Director of Belite Bio, Inc, sold 367 shares of common stock on August 12, 2026.

Yu-Hsin Lin, Chief Executive Officer and a Director of Belite Bio, Inc, sold 365 shares of common stock on August 12, 2026.

Hendrik Peter Scholl, Chief Medical Officer of Belite Bio, Inc., reported the sale of American depositary shares totaling 7,820 shares on June 16, 2026.

Chief Scientific Officer Nathan L. Mata sold 666 American depositary shares of Belite Bio, Inc. via a Rule 10b5-1 trading plan.

Belite Bio's Chief Scientific Officer, Nathan L. Mata, reported the sale of American depositary shares under a pre-arranged trading plan.

Belite Bio's Chief Scientific Officer, Nathan L. Mata, reported the sale of American depositary shares under a pre-arranged trading plan.

Belite Bio's Chief Scientific Officer, Nathan L. Mata, sold a significant number of American depositary shares under a pre-arranged trading plan.

Belite Bio's Chief Scientific Officer, Nathan L. Mata, reported the sale of American depositary shares under a pre-arranged trading plan.

Belite Bio's Chief Scientific Officer, Nathan L. Mata, sold a significant number of American depositary shares under a pre-arranged trading plan.

Belite Bio's Chief Scientific Officer, Nathan L. Mata, reported the sale of American depositary shares valued at over $1.2 million through a pre-arranged trading plan.

Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares of Belite Bio, Inc. via a 10b5-1 trading plan.

Chief Scientific Officer Nathan L. Mata sold 1,002 American depositary shares of Belite Bio, Inc. on April 23, 2026, pursuant to a pre-arranged trading plan.

Belite Bio CEO Lin Yu-Hsin acquired 10,000 ordinary shares upon the vesting of restricted stock units.

Hendrik Peter Scholl, Chief Medical Officer of Belite Bio, Inc., reported the vesting of 10,000 ordinary share options on April 21, 2026, following the satisfaction of performance criteria.

Belite Bio's Chief Scientific Officer, Nathan L. Mata, sold a significant number of American depositary shares under a pre-arranged trading plan.

Belite Bio, Inc. reports that Chief Financial Officer Hao-Yuan Chuang acquired 10,000 ordinary shares upon the vesting of restricted stock units.

Belite Bio's Chief Scientific Officer, Nathan L. Mata, sold a significant number of American depositary shares under a pre-arranged trading plan.

Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares of Belite Bio, Inc. pursuant to a pre-established Rule 10b5-1 trading plan.

Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares of Belite Bio, Inc. pursuant to a pre-established Rule 10b5-1 trading plan.

Chief Scientific Officer Nathan L. Mata sold 1,001 American depositary shares of Belite Bio, Inc. pursuant to a pre-established Rule 10b5-1 trading plan.

Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares of Belite Bio, Inc. via a pre-arranged 10b5-1 trading plan.

Belite Bio CEO Lin Yu-Hsin has sold a total of 8,700 American depositary shares under a pre-arranged trading plan, generating proceeds of approximately $1.58 million.

Belite Bio Director Chen Wan-Shan reported a sale of American depositary shares under a pre-arranged trading plan.

Belite Bio's Chief Financial Officer, Hao-Yuan Chuang, has sold a significant number of American depositary shares under a pre-arranged trading plan.

Chief Scientific Officer Nathan L. Mata vested 144,868 stock options following the achievement of performance criteria.

CEO Yu-Hsin Lin of Belite Bio, Inc. reported the vesting of 206,954 stock options following the achievement of performance criteria.